# US 2026/0108564 A1 · Methods and compositions for reducing clostridium difficile infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0108564 A1
- Document ID: US20260108564A1
- Status: Published application
- Kind: A1
- Application number: 19/303,846
- Filed: 2025-08-19
- Published: 2026-04-23
- Earliest claimed: 2014-05-19
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan-Kettering Cancer Center
- Inventors: Eric Pamer; Charlie Buffie; Peter McKenney
- Web page: https://patentgrep.com/patent/US20260108564A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 38/443: {acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12Q 1/26: involving oxidoreductase
- C12Y 101/01159: 7-Alpha-hydroxysteroid dehydrogenase (1.1.1.159)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim 43

A composition comprising a first isolated bacteria or spores thereof being Clostridium scindens expressing an enzyme that converts a bile acid to a secondary bile acid and a second isolated bacteria or spores thereof being selected from the group consisting of Clostridium hiranonis, Clostridium hylemonae, Clostridium sordellii, and a combination thereof.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the composition further comprises isolated bacteria or spores thereof being selected from the group consisting of Barnesiella intestihominis, Blautia hansenii, and Pseudoflavonifractor capillosus.

### Claim 45 (depends on 43)

The composition of claim 43, wherein the composition is formulated for oral or rectal administration.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the composition formulated for oral or rectal administration further comprises a probiotic bacterium, probiotic yeast, or a combination thereof.

### Claim 47 (depends on 45)

The composition of claim 45, wherein the composition formulated for oral or rectal administration is a liquid, suspension, dried powder, tablet, capsule or food product.

### Claim 48 (depends on 43)

A method for reducing the risk of Clostridium difficile infection in a subject, reducing the severity of Clostridium difficile infection in a subject, decreasing the amount of Clostridium difficile toxin in a subject, increasing resistance to Clostridium difficile infection in a subject, reducing risk of developing Clostridium difficile-associated disease in a subject, treating Clostridium difficile-associated disease in a subject, or preventing a Clostridium difficile-associated disease in a subject
comprising administering, to a subject in need of such treatment, an effective amount of the composition of claim 43.

### Claim 49 (depends on 48)

The method of claim 48, wherein said effective amount of the composition is effective to cause engraftment of the administered bacteria in the intestine of the subject, as determined by 16S rRNA sequencing of subject feces two days following administration.

### Claim 50 (depends on 48)

The method of claim 48, wherein the composition is administered to the subject in an amount effective to inhibit proliferation of Clostridium difficile in the subject.

### Claim 51 (depends on 48)

The method of claim 48, wherein the composition is administered to the subject in an amount effective to reduce one or more clinical symptoms of Clostridium difficile infection selected from the group consisting of frequency and/or volume of diarrhea; fever; abdominal cramping, pain, and/or tenderness; elevated level white blood cells in the blood; loss of serum albumin; weight loss; appearance of pseudomembrane in the intestinal and/or rectal mucosa; and combinations thereof.

### Claim 52 (depends on 48)

The method of claim 48, further comprising administering to the subject, an antibiotic, an immunotherapeutic agent, an herbal remedy, a probiotic, or combinations thereof.

### Claim 53 (depends on 48)

The method of claim 48, further comprising identifying the subject with the Clostridium difficile infection, or at risk for Clostridium difficile infection, comprising
obtaining an intestinal microbiota sample from the subject and determining the level of one or more bacterium present in the intestinal microbiota sample that can convert a primary bile acid to a secondary bile acid;
comparing the level of the one or more bacterium in the sample with a reference bacterium level; and
administering the composition to the subject when the level of one or more bacterium in the sample is lower than the bacterium reference level.

### Claim 54 (depends on 48)

The method of claim 48, further comprising identifying the subject with the Clostridium difficile infection, or at risk for Clostridium difficile infection, comprising
obtaining an intestinal microbiota sample from the subject and determining the activity or level of 7α-hydroxysteroid dehydrogenase enzyme present in the intestinal microbiota sample;
comparing the activity or level of 7α-hydroxysteroid dehydrogenase enzyme in the sample with a reference 7α-hydroxysteroid dehydrogenase enzyme activity or level; and
administering the composition to the subject when the activity or level of 7α-hydroxysteroid dehydrogenase enzyme in the sample is lower than the reference 7α-hydroxysteroid dehydrogenase enzyme activity or level.

### Claim 55 (depends on 46)

A kit comprising the composition of claim 46.

### Claim 56 (depends on 53)

The method of claim 53, wherein the one or more bacterium is selected from the group consisting of Clostridium scindens, Clostridium hiranonis, Clostridium hylemonae, Clostridium perfringens, Clostridium sordellii, Proteocatella sphenisci, Lachnospiraceae 5_1_57FAA, Clostridiales VE202-05, Clostridiales VE202-26, and combinations thereof.

### Claim 57 (depends on 53)

The method of claim 53, further comprising administering an antibiotic to the subject, wherein, when the level of one or more bacterium in the sample is equal to or greater than the bacterium reference level, the antibiotic administered to the subject is not an antibiotic selected from the group consisting of a β-lactam antibiotic, clindamycin, a cephalosporin, a quinolone antibiotic, levofloxacin, fluoroquinolone, a macrolide antibiotic, trimethoprim, and a sulfonamide antibiotic.

### Claim 58 (depends on 48)

The method of claim 48, further comprising identifying the subject with the Clostridium difficile infection, or at risk for Clostridium difficile infection, comprising
obtaining a fecal sample from the subject and quantifying the level of bile acid-inducible (bai) 7α/β-dehydroxylation operon nucleic acid present in the fecal sample;
comparing the level of bile acid-inducible (bai) 7α/β-dehydroxylation operon nucleic acid in the fecal sample with a reference bile acid-inducible (bai) 7α/β-dehydroxylation operon nucleic acid level; and
administering the composition to the subject when the level of bile acid-inducible (bai) 7α/β-dehydroxylation operon nucleic acid in the fecal sample is lower than the reference level.

### Claim 59 (depends on 43)

A method of reducing risk of developing Clostridium difficile-associated disease in a subject receiving antibiotic therapy, comprising administering, to a subject in need of such treatment, an effective amount of the composition of claim 43.

### Claim 60 (depends on 43)

A method of treating Clostridium difficile-associated disease in a subject receiving antibiotic therapy, comprising administering, to a subject in need of such treatment, an effective amount of the composition of claim 43.

### Claim 61 (depends on 43)

A method of preventing a Clostridium difficile-associated disease in a subject, comprising administering, to a subject in need of such treatment, an effective amount of the composition of claim 43, wherein the Clostridium difficile-associated disease is Clostridium difficile colitis or pseudomembranous colitis.

### Claim 62 (depends on 43)

A method of treating a Clostridium difficile-associated disease in a subject, comprising administering, to a subject in need of such treatment, an effective amount of the composition of claim 43, wherein the Clostridium difficile-associated disease is Clostridium difficile colitis or pseudomembranous colitis.
